Literature DB >> 23312215

Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.

Iliana Doycheva1, Niraj Patel, Michael Peterson, Rohit Loomba.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) frequently coexist due to shared risk factors. Their rising prevalence parallels the growing epidemic of obesity and insulin resistance (IR). In patients with T2DM and biopsy-proven NAFLD, a significantly higher prevalence of nonalcoholic steatohepatitis (NASH) (63-87%), any fibrosis (22-60%), and advanced fibrosis (4-9%) is noted. Possible risk factors for more advanced liver disease include concomitant metabolic syndrome with three or more components, visceral obesity, older age, increased duration of diabetes, and family history of diabetes. Liver biopsy is strongly suggested in these patients. Cardiovascular disease (CVD) and malignancy are the leading causes of death in this population, but a growing body of evidence shows liver-related mortality as an important cause of death, including an increased rate of hepatocellular carcinoma (HCC) in diabetes. The presence of NAFLD in T2DM is also associated with increased overall mortality. We aim with this review to summarize the results from studies investigating NAFLD in T2DM and to outline the factors that predict more advanced liver histology as well as the impact of these hepatic changes on CVD, overall and liver-related mortality.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23312215      PMCID: PMC4167586          DOI: 10.1016/j.jdiacomp.2012.10.008

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  75 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

3.  Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus.

Authors:  Yuki Kimura; Hideyuki Hyogo; Tomokazu Ishitobi; Yoshitaka Nabeshima; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol Hepatol       Date:  2011-03       Impact factor: 4.029

4.  Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Vera L N Pannain; Adriana C Bottino; Guilherme F M Rezende; Claudia R L Cardoso; Gil F Salles
Journal:  Liver Int       Date:  2011-02-20       Impact factor: 5.828

5.  Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

Authors:  Camilo Boza; Arnoldo Riquelme; Luis Ibañez; Ignacio Duarte; Enrique Norero; Paola Viviani; Alejandro Soza; Jose Ignacio Fernandez; Alejandro Raddatz; Sergio Guzman; Marco Arrese
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

6.  Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter?

Authors:  Jeremy P Domanski; Stephen J Park; Stephen A Harrison
Journal:  J Clin Gastroenterol       Date:  2012 May-Jun       Impact factor: 3.062

7.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

8.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

9.  Diabetic hepatosclerosis: a 10-year autopsy series.

Authors:  Guilan Chen; Elizabeth M Brunt
Journal:  Liver Int       Date:  2009-01-08       Impact factor: 5.828

10.  Clinical resolution of glycogenic hepatopathy following improved glycemic control.

Authors:  Rachel M Hudacko; Aram V Manoukian; Stephen H Schneider; Billie Fyfe
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

View more
  14 in total

Review 1.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

Review 2.  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.

Authors:  Vasilios G Athyros; Konstantinos Tziomalos; Niki Katsiki; Michael Doumas; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 3.  NAFLD and diabetes mellitus.

Authors:  Herbert Tilg; Alexander R Moschen; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

4.  Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients.

Authors:  Alexandra Sima; Romulus Timar; Adrian Vlad; Bogdan Timar; Mihaela Rosu; Isabel Dan; Roxana Sirli; Alina Popescu; Ioan Sporea
Journal:  Wien Klin Wochenschr       Date:  2014-03-21       Impact factor: 1.704

5.  Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.

Authors:  Kathleen E Corey; Matthew J Klebanoff; Angela C Tramontano; Raymond T Chung; Chin Hur
Journal:  Dig Dis Sci       Date:  2016-01-29       Impact factor: 3.199

6.  NON-INVASIVE ASSESSMENT OF LIVER STEATOSIS AND FIBROSIS USING TRANSIENT ELASTOGRAPHY AND CONTROLLED ATTENUATION PARAMETER IN TYPE 2 DIABETES PATIENTS.

Authors:  A Sima; I Sporea; R Timar; M Vlad; A Braha; A Popescu; S Nistorescu; R Mare; R Sirli; A Albai; O Albai; L Diaconu; T Sorescu; S Popescu; L Sima
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

7.  Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases.

Authors:  Evan J Raff; Donny Kakati; Joseph R Bloomer; Mohamed Shoreibah; Khalid Rasheed; Ashwani K Singal
Journal:  J Clin Transl Hepatol       Date:  2015-03-15

8.  Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.

Authors:  Jessica Bazick; Michele Donithan; Brent A Neuschwander-Tetri; David Kleiner; Elizabeth M Brunt; Laura Wilson; Ed Doo; Joel Lavine; James Tonascia; Rohit Loomba
Journal:  Diabetes Care       Date:  2015-04-17       Impact factor: 19.112

9.  Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls.

Authors:  Niraj S Patel; Michael R Peterson; Grace Y Lin; Ariel Feldstein; Bernd Schnabl; Ricki Bettencourt; Ekihiro Seki; Claude B Sirlin; Rohit Loomba
Journal:  Gastroenterol Res Pract       Date:  2013-11-17       Impact factor: 2.260

10.  Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis.

Authors:  Marta Gonzalez Rozas; Lidia Hernanz Roman; Diego Gonzalez Gonzalez; José Luis Pérez-Castrillón
Journal:  Case Rep Endocrinol       Date:  2016-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.